Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail

<i>Coot</i> : model-building tools for molecular graphics

Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571 · see citing works

<i>PHENIX</i> : a comprehensive Python-based system for macromolecular structure solution

Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716 · see citing works

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969 · see citing works

<i>Phaser</i> crystallographic software

McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612 · see citing works

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286 · see citing works

<i>XDS</i>

Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463 · see citing works

Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega

Sievers, F., Wilm, A., Dineen, D., Gibson, T., Karplus, K., Li, W.-Z., Lopez, R., McWilliam, H., Remmert, M., Söding, J., et al. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.75 · Cited by 15,576 · see citing works

WebLogo: A Sequence Logo Generator: Figure 1Preprint

Crooks, G. E., Hon, G. C., Chandonia, J., & Brenner, S. E. (2004) · Genome Research · doi:10.1101/gr.849004 · Cited by 12,433 · see citing works

Overview of the <i>CCP</i> 4 suite and current developments

Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353 · see citing works

MUSCLE: a multiple sequence alignment method with reduced time and space complexity

Edgar, R. (2004) · BMC Bioinformatics · doi:10.1186/1471-2105-5-113 · Cited by 8,948 · see citing works

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897 · see citing works

PHENIX: a comprehensive Python-based system for macromolecular structure solution

Adams, P. D., Afonine, P. V., Bunkòczi, G., Chen, V. B., Davis, I., Echols, N., Headd, J. J., Hung, L., Kapral, G. J., Grosse‐Kunstleve, R. W., et al. (2012) · International Tables for Crystallography · doi:10.1107/97809553602060000865 · Cited by 7,334 · see citing works

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Letko, M., Marzi, A., & Munster, V. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0688-y · Cited by 3,109 · see citing works

Antibody responses to SARS-CoV-2 in patients with COVID-19

Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Liao, P., Qiu, J.-F., Lin, Y., Cai, X.-F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0897-1 · Cited by 2,876 · see citing works

Detection of a SARS-CoV-2 variant of concern in South Africa

Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2021) · Nature · doi:10.1038/s41586-021-03402-9 · Cited by 2,510 · see citing works

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · Nature · doi:10.1038/s41586-021-03398-2 · Cited by 2,312 · see citing works

Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding

Starr, T. N., Greaney, A. J., Hilton, S. K., Ellis, D., Crawford, K. H. D., Dingens, A. S., Navarro, M. J., Bowen, J. E., Tortorici, M. A., Walls, A. C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.012 · Cited by 1,956 · see citing works

Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals

Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853 · see citing works

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Ju, B., Zhang, Q., Ge, J., Wang, R., Sun, J., Ge, X., Yu, J., Shan, S., Zhou, B., Song, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2380-z · Cited by 1,667 · see citing works

Spike mutation D614G alters SARS-CoV-2 fitness

Plante, J. A., Liu, Y., Liu, J., Xia, H., Johnson, B. A., Lokugamage, K. G., Zhang, X., Muruato, A. E., Zou, J., Fontes-Garfias, C. R., et al. (2021) · Nature · doi:10.1038/s41586-020-2895-3 · Cited by 1,558 · see citing works

The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity

Li, Q., Wu, J., Nie, J., Zhang, L., Hao, H., Liu, S., Zhao, C., Zhang, Q., Liu, H., Nie, L., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.012 · Cited by 1,420 · see citing works

Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology

Piccoli, L., Park, Y.-J., Tortorici, M. A., Czudnochowski, N., Walls, A. C., Beltramello, M., Silacci-Fregni, C., Pinto, D., Rosen, L. E., Bowen, J. E., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.037 · Cited by 1,395 · see citing works

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Liu, L., Wang, P., Nair, M. S., Yu, J., Rapp, M., Wang, Q., Luo, Y., Chan, J. F.-W., Sahi, V., Figueroa, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2571-7 · Cited by 1,349 · see citing works

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Wang, Z., Schmidt, F., Weisblum, Y., Muecksch, F., Barnes, C. O., Finkin, S., Schaefer-Babajew, D., Cipolla, M., Gaebler, C., Lieberman, J. A., et al. (2021) · Nature · doi:10.1038/s41586-021-03324-6 · Cited by 1,343 · see citing works

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

Weisblum, Y., Schmidt, F., Zhang, F., DaSilva, J., Poston, D., Lorenzi, J. C., Muecksch, F., Rutkowska, M., Hoffmann, H.-H., Michailidis, E., et al. (2020) · eLife · doi:10.7554/elife.61312 · Cited by 1,308 · cited 1× · see citing works

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

Hsieh, C.-L., Goldsmith, J. A., Schaub, J. M., DiVenere, A. M., Kuo, H.-C., Javanmardi, K., Le, K. C., Wrapp, D., Lee, A. G., Liu, Y., et al. (2020) · Science · doi:10.1126/science.abd0826 · Cited by 1,303 · see citing works

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Shi, R., Shan, C., Duan, X., Chen, Z., Liu, P., Song, J., Song, T., Bi, X., Han, C., Wu, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2381-y · Cited by 1,286 · see citing works

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Rogers, T. F., Zhao, F., Huang, D., Beutler, N., Burns, A., He, W.-T., Limbo, O., Smith, C., Song, G., Woehl, J., et al. (2020) · Science · doi:10.1126/science.abc7520 · Cited by 1,230 · see citing works

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

Hansen, J., Baum, A., Pascal, K. E., Russo, V., Giordano, S., Wloga, E., Fulton, B. O., Yan, Y., Koon, K., Patel, K., et al. (2020) · Science · doi:10.1126/science.abd0827 · Cited by 1,210 · see citing works

Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells

Cao, Y., Su, B., Guo, X., Sun, W., Deng, Y., Bao, L., Zhu, Q., Zhang, X., Zheng, Y., Geng, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.025 · Cited by 1,188 · see citing works

Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies

Greaney, A. J., Loes, A. N., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021) · Cell Host &amp; Microbe · doi:10.1016/j.chom.2021.02.003 · Cited by 1,178 · cited 2× · see citing works

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

Wibmer, C. K., Ayres, F., Hermanus, T., Madzivhandila, M., Kgagudi, P., Oosthuysen, B., Lambson, B. E., de Oliveira, T., Vermeulen, M., van der Berg, K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01285-x · Cited by 1,147 · see citing works

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

Brouwer, P. J. M., Caniels, T. G., van der Straten, K., Snitselaar, J. L., Aldon, Y., Bangaru, S., Torres, J. L., Okba, N. M. A., Claireaux, M., Kerster, G., et al. (2020) · Science · doi:10.1126/science.abc5902 · Cited by 1,140 · see citing works

Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses

Sui, J., Hwang, W. C., Perez, S., Ge, W., Aird, D. R., Chen, L., Santelli, E., Stec, B., Cadwell, G., Ali, M., et al. (2009) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1566 · Cited by 1,132 · see citing works

Potently neutralizing and protective human antibodies against SARS-CoV-2

Zost, S. J., Gilchuk, P., Case, J. B., Binshtein, E., Chen, R. E., Nkolola, J. P., Schäfer, A., Reidy, J. X., Trivette, A., Nargi, R. S., et al. (2020) · Nature · doi:10.1038/s41586-020-2548-6 · Cited by 1,041 · see citing works

Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition

Greaney, A. J., Starr, T. N., Gilchuk, P., Zost, S. J., Binshtein, E., Loes, A. N., Hilton, S. K., Huddleston, J., Eguia, R., Crawford, K. H. D., et al. (2021) · Cell Host &amp; Microbe · doi:10.1016/j.chom.2020.11.007 · Cited by 1,016 · see citing works

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies

Chen, R. E., Zhang, X., Case, J. B., Winkler, E. S., Liu, Y., VanBlargan, L. A., Liu, J., Errico, J. M., Xie, X., Suryadevara, N., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01294-w · Cited by 881 · see citing works

Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing

Wu, X., Zhou, T., Zhu, J., Zhang, B., Georgiev, I. S., Wang, C., Chen, X., Longo, N. S., Louder, M. K., McKee, K., et al. (2011) · Science · doi:10.1126/science.1207532 · Cited by 785 · see citing works

Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion

Benton, D. J., Wrobel, A. G., Xu, P., Roustan, C., Martin, S. R., Rosenthal, P. B., Skehel, J. J., & Gamblin, S. J. (2020) · Nature · doi:10.1038/s41586-020-2772-0 · Cited by 764 · see citing works

Prospective mapping of viral mutations that escape antibodies used to treat COVID-19

Starr, T. N., Greaney, A. J., Addetia, A., Hannon, W. W., Choudhary, M. C., Dingens, A. S., Li, J. Z., & Bloom, J. D. (2021) · Science · doi:10.1126/science.abf9302 · Cited by 743 · see citing works

Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization

Liu, Z., VanBlargan, L. A., Bloyet, L.-M., Rothlauf, P. W., Chen, R. E., Stumpf, S., Zhao, H., Errico, J. M., Theel, E. S., Liebeskind, M. J., et al. (2021) · Cell Host &amp; Microbe · doi:10.1016/j.chom.2021.01.014 · Cited by 725 · see citing works

Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020

Leung, K., Shum, M. H., Leung, G. M., Lam, T. T., & Wu, J. T. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.26.1.2002106 · Cited by 694 · see citing works

Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma

Network for Genomic Surveillance in South Africa, Cele, S., COMMIT-KZN Team, Gazy, I., Jackson, L., Hwa, S.-H., Tegally, H., Lustig, G., Giandhari, J., Pillay, S., et al. (2021) · Nature · doi:10.1038/s41586-021-03471-w · Cited by 651 · see citing works

Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant

Deng, X., Garcia-Knight, M. A., Khalid, M. M., Servellita, V., Wang, C., Morris, M. K., Sotomayor-González, A., Glasner, D. R., Reyes, K. R., Gliwa, A. S., et al. (2021) · Cell · doi:10.1016/j.cell.2021.04.025 · Cited by 651 · see citing works

An Infectious cDNA Clone of SARS-CoV-2

Xie, X., Muruato, A., Lokugamage, K. G., Narayanan, K., Zhang, X., Zou, J., Liu, J., Schindewolf, C., Bopp, N. E., Aguilar, P. V., et al. (2020) · Cell Host &amp; Microbe · doi:10.1016/j.chom.2020.04.004 · Cited by 647 · see citing works

Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization

Wang, P., Casner, R. G., Nair, M. S., Wang, M., Yu, J., Cerutti, G., Liu, L., Kwong, P. D., Huang, Y., Shapiro, L., et al. (2021) · Cell Host &amp; Microbe · doi:10.1016/j.chom.2021.04.007 · Cited by 636 · see citing works

Emergence of SARS-CoV-2 B.1.1.7 Lineage — United States, December 29, 2020–January 12, 2021

Galloway, S. E., Paul, P., MacCannell, D., Johansson, M., Brooks, J., MacNeil, A., Slayton, R., Tong, S., Silk, B., Armstrong, G., et al. (2021) · MMWR. Morbidity and mortality weekly report · doi:10.15585/mmwr.mm7003e2 · Cited by 619 · see citing works

Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity

Thomson, E. C., Rosen, L. E., Shepherd, J. G., Spreafico, R., da Silva Filipe, A., Wojcechowskyj, J. A., Davis, C., Piccoli, L., Pascall, D. J., Dillen, J., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.037 · Cited by 606 · see citing works

Structural basis of a shared antibody response to SARS-CoV-2

Yuan, M., Liu, H., Wu, N. C., Lee, C.-C. D., Zhu, X., Zhao, F., Huang, D., Yu, W., Hua, Y., Tien, H., et al. (2020) · Science · doi:10.1126/science.abd2321 · Cited by 589 · see citing works

SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effects

Wrobel, A. G., Benton, D. J., Xu, P., Roustan, C., Martin, S. R., Rosenthal, P. B., Skehel, J. J., & Gamblin, S. J. (2020) · Nature Structural &amp; Molecular Biology · doi:10.1038/s41594-020-0468-7 · Cited by 544 · see citing works

Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion

Walls, A. C., Tortorici, M. A., Snijder, J., Xiong, X., Bosch, B., Rey, F. A., & Veesler, D. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1708727114 · Cited by 539 · see citing works

REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters

Baum, A., Ajithdoss, D., Copin, R., Zhou, A., Lanza, K., Negron, N., Ni, M., Wei, Y., Mohammadi, K., Musser, B., et al. (2020) · Science · doi:10.1126/science.abe2402 · Cited by 517 · see citing works

Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms

Tortorici, M. A., Beltramello, M., Lempp, F. A., Pinto, D., Dang, H. V., Rosen, L. E., McCallum, M., Bowen, J., Minola, A., Jaconi, S., et al. (2020) · Science · doi:10.1126/science.abe3354 · Cited by 510 · see citing works

Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design

Rappuoli, R., Bottomley, M. J., D’Oro, U., Finco, O., & Gregorio, E. D. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20151960 · Cited by 438 · see citing works

Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies

Greaney, A. J., Starr, T. N., Barnes, C. O., Weisblum, Y., Schmidt, F., Caskey, M., Gaebler, C., Cho, A., Agudelo, M., Finkin, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24435-8 · Cited by 433 · see citing works

Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein

Zost, S. J., Gilchuk, P., Chen, R. E., Case, J. B., Reidy, J. X., Trivette, A., Nargi, R. S., Sutton, R. E., Suryadevara, N., Chen, E. C., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0998-x · Cited by 423 · see citing works

Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2

Case, J. B., Rothlauf, P. W., Chen, R. E., Liu, Z., Zhao, H., Kim, A. S., Bloyet, L.-M., Zeng, Q., Tahan, S., Droit, L., et al. (2020) · Cell Host &amp; Microbe · doi:10.1016/j.chom.2020.06.021 · Cited by 410 · see citing works

Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil

Voloch, C. M., Silva F, R. D., de Almeida, L. G. P., Cardoso, C. C., Brustolini, O. J., Gerber, A. L., Guimarães, A. P. D. C., Mariani, D., Costa, R. M. D., Ferreira, O. C., et al. (2020) · doi:10.1101/2020.12.23.20248598 · Cited by 372 · cited 3× · see citing works

Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil

Voloch, C. M., da Silva Francisco, R., de Almeida, L. G. P., Cardoso, C. C., Brustolini, O. J., Gerber, A. L., Guimarães, A. P. D. C., Mariani, D., da Costa, R. M., Ferreira, O. C., et al. (2021) · Journal of Virology · doi:10.1128/jvi.00119-21 · Cited by 372 · see citing works

The antigenic anatomy of SARS-CoV-2 receptor binding domain

Dejnirattisai, W., Zhou, D., Ginn, H. M., Duyvesteyn, H. M. E., Supasa, P., Case, J. B., Zhao, Y., Walter, T. S., Mentzer, A. J., Liu, C., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.032 · Cited by 371 · see citing works

Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus

Giang, E., Dorner, M., Prentoe, J. C., Dreux, M., Evans, M. J., Bukh, J., Rice, C. M., Ploß, A., Burton, D. R., & Law, M. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1114927109 · Cited by 346 · see citing works

BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants

Liu, J., Liu, Y., Xia, H., Zou, J., Weaver, S. C., Swanson, K. A., Cai, H., Cutler, M., Cooper, D., Muik, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03693-y · Cited by 342 · see citing works

Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses

Joyce, M. G., Wheatley, A. K., Thomas, P. V., Chuang, G.-Y., Soto, C., Bailer, R. T., Druz, A., Georgiev, I. S., Gillespie, R. A., Kanekiyo, M., et al. (2016) · Cell · doi:10.1016/j.cell.2016.06.043 · Cited by 333 · see citing works

Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients

Kreer, C., Zehner, M., Weber, T., Ercanoglu, M. S., Gieselmann, L., Rohde, C., Halwe, S., Korenkov, M., Schommers, P., Vanshylla, K., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.044 · Cited by 313 · see citing works

Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors

Zhou, T., Lynch, R. M., Chen, L., Acharya, P., Wu, X., Doria-Rose, N. A., Joyce, M. G., Lingwood, D., Soto, C. S., Bailer, R. T., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.007 · Cited by 311 · see citing works

High frequency of shared clonotypes in human B cell receptor repertoires

Soto, C., Bombardi, R. G., Branchizio, A., Kose, N., Matta, P., Sevy, A. M., Sinkovits, R. S., Gilchuk, P., Finn, J. A., & Crowe, J. E. (2019) · Nature · doi:10.1038/s41586-019-0934-8 · Cited by 294 · see citing works

Rapid development of broadly influenza neutralizing antibodies through redundant mutations

Pappas, L., Foglierini, M., Piccoli, L., Kallewaard, N. L., Turrini, F., Silacci, C., Fernandez-Rodriguez, B. M., Agatic, G., Giacchetto-Sasselli, I., Pellicciotta, G., et al. (2014) · Nature · doi:10.1038/nature13764 · Cited by 287 · see citing works

Structural basis of tyrosine sulfation and V H -gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120

Huang, C.-C., Venturi, M., Majeed, S., Moore, M. J., Phogat, S. K., Zhang, M.-Y., Dimitrov, D. S., Hendrickson, W. A., Robinson, J. E., Sodroski, J., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308527100 · Cited by 275 · see citing works

Inferring the shape of global epistasis

Otwinowski, J., McCandlish, D. M., & Plotkin, J. B. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1804015115 · Cited by 243 · see citing works

Human B Cell Clonal Expansion and Convergent Antibody Responses to SARS-CoV-2

Nielsen, S. C. A., Yang, F., Jackson, K., Hoh, R. A., Röltgen, K., Jean, G. H., Stevens, B., Lee, J.-Y., Rustagi, A., Rogers, A. J., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.09.002 · Cited by 236 · see citing works

GlyProt: in silico glycosylation of proteins

Bohne-Lang, A., & der Lieth, C. W. V. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki385 · Cited by 207 · see citing works

Diversion of HIV-1 vaccine–induced immunity by gp41-microbiota cross-reactive antibodies

Williams, W. B., Liao, H., Moody, M. A., Kepler, T. B., Alam, S. M., Gao, F., Wiehe, K. J., Trama, A. M., Jones, K. L., Zhang, R., et al. (2015) · Science · doi:10.1126/science.aab1253 · Cited by 197 · see citing works

SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma

Andreano, E., Piccini, G., Licastro, D., Casalino, L., Johnson, N., Paciello, I., Monego, S. D., Pantano, E., Manganaro, N., Manenti, A., et al. (2021) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.2103154118 · Cited by 187 · see citing works

Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance

Bailey, J. R., Flyak, A. I., Cohen, V. J., Li, H., Wasilewski, L. N., Snider, A. E., Wang, S., Learn, G. H., Kose, N., Loerinc, L. B., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.92872 · Cited by 138 · see citing works

SARS-CoV-2 growth, furin-cleavage-site adaptation and neutralization using serum from acutely infected hospitalized COVID-19 patients

Klimstra, W. B., Tilston-Lunel, N. L., Nambulli, S., Boslett, J., McMillen, C. M., Gilliland, T., Dunn, M. D., Sun, C., Wheeler, S. E., Wells, A., et al. (2020) · Journal of General Virology · doi:10.1099/jgv.0.001481 · Cited by 137 · see citing works

H5N1 Vaccine–Elicited Memory B Cells Are Genetically Constrained by the IGHV Locus in the Recognition of a Neutralizing Epitope in the Hemagglutinin Stem

Wheatley, A. K., Whittle, J. R. R., Lingwood, D., Kanekiyo, M., Yassine, H. M., Steven, S., Narpala, S., Prabhakaran, M. S., Matus‐Nicodemos, R., Bailer, R. T., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402835 · Cited by 98 · see citing works

SARS-CoV-2 S1 and N-based serological assays reveal rapid seroconversion and induction of specific antibody response in COVID-19 patients

Algaissi, A., Alfaleh, M. A., Hala, S., Abujamel, T. S., Alamri, S. S., Almahboub, S., Alluhaybi, K., Hobani, H. I., Alsulaiman, R. M., Alharbi, R. H., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-73491-5 · Cited by 87 · see citing works

The Measurement of Human Spermatozoan Motility

Janick, J., & Macleod, J. (1970) · Fertility and Sterility · doi:10.1016/s0015-0282(16)37327-7 · Cited by 78 · see citing works

Infant and Adult Human B Cell Responses to Rotavirus Share Common Immunodominant Variable Gene Repertoires

Weitkamp, J.-H., Kallewaard, N. L., Kusuhara, K., Bures, E., Williams, J. V., LaFleur, B., Greenberg, H. B., & Crowe, J. E. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.9.4680 · Cited by 68 · see citing works

An Extensive Meta-Metagenomic Search Identifies SARS-CoV-2-Homologous Sequences in Pangolin Lung Viromes

Wahba, L., Jain, N., Fire, A. Z., Shoura, M. J., Artiles, K. L., McCoy, M. J., & Jeong, D. (2020) · mSphere · doi:10.1128/msphere.00160-20 · Cited by 60 · see citing works

Transmission of SARS-CoV-2 from humans to animals and potential host adaptationPreprint

Tan, C. C. S., Lam, S. D., Richard, D., Owen, C. J., Berchtold, D., Orengo, C. A., Nair, M. S., Kuchipudi, S. V., Kapur, V., van Dorp, L., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.16.384743 · Cited by 60 · see citing works

Immunodominance of the VH1–46 Antibody Gene Segment in the Primary Repertoire of Human Rotavirus-Specific B Cells Is Reduced in the Memory Compartment through Somatic Mutation of Nondominant Clones

Tian, C., Luskin, G. K., Dischert, K. M., Higginbotham, J. N., Shepherd, B. E., & Crowe, J. E. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.5.3279 · Cited by 48 · see citing works

Host barriers to SARS-CoV-2 demonstrated by ferrets in a high-exposure domestic setting

Sawatzki, K., Hill, N. J., Puryear, W. B., Foss, A. D., Stone, J. J., & Runstadler, J. A. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2025601118 · Cited by 43 · see citing works

Of sound mind

Fitzgerald, M., & Berman, D. S. (1994) · Nature · doi:10.1038/368092b0 · Cited by 11 · see citing works

SARS-CoV-2 escape <i>in vitro</i> from a highly neutralizing COVID-19 convalescent plasma

Andreano, E., Piccini, G., Licastro, D., Casalino, L., Johnson, N. V., Paciello, I., Monego, S. D., Pantano, E., Manganaro, N., Manenti, A., et al. (2020) · doi:10.1101/2020.12.28.424451 · cited 1×

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

Cao, Y., Wang, J., Jian, F., Xiao, T., Song, W., Yisimayi, A., Huang, W., Li, Q., Wang, P., An, R., et al. (2022) · Nature · doi:10.1038/s41586-021-04385-3 · Cited by 2,006 · see citing works

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

Cameroni, E., Bowen, J. E., Rosen, L. E., Saliba, C., Zepeda, S. K., Culap, K., Pinto, D., VanBlargan, L. A., Marco, A. D., di Iulio, J., et al. (2021) · Nature · doi:10.1038/s41586-021-04386-2 · Cited by 1,043 · see citing works

mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant

Garcia-Beltran, W. F., St. Denis, K. J., Hoelzemer, A., Lam, E. C., Nitido, A. D., Sheehan, M. L., Berrios, C., Ofoman, O., Chang, C. C., Hauser, B. M., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.033 · Cited by 1,045 · see citing works

Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19

Levin, M. J., Ustianowski, A., Wit, S. D., Launay, O., Avila, M., Templeton, A., Yuan, Y., Seegobin, S., Ellery, A., Levinson, D. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116620 · Cited by 691 · see citing works

Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum

Tuekprakhon, A., Nutalai, R., Dijokaite-Guraliuc, A., Zhou, D., Ginn, H. M., Selvaraj, M., Liu, C., Mentzer, A. J., Supasa, P., Duyvesteyn, H. M. E., et al. (2022) · Cell · doi:10.1016/j.cell.2022.06.005 · Cited by 677 · see citing works

Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance

Chen, J., Wang, R., Gilby, N. B., & Wei, G. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c01451 · Cited by 688 · see citing works

Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement

McCallum, M., Czudnochowski, N., Rosen, L. E., Zepeda, S. K., Bowen, J. E., Walls, A. C., Hauser, K., Joshi, A., Stewart, C., Dillen, J. R., et al. (2022) · Science · doi:10.1126/science.abn8652 · Cited by 535 · see citing works

Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016

Starr, T. N., Greaney, A. J., Dingens, A. S., & Bloom, J. D. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100255 · Cited by 470 · see citing works

The antigenic anatomy of SARS-CoV-2 receptor binding domain

Dejnirattisai, W., Zhou, D., Ginn, H. M., Duyvesteyn, H. M. E., Supasa, P., Case, J. B., Zhao, Y., Walter, T. S., Mentzer, A. J., Liu, C., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.032 · Cited by 371 · see citing works

Tackling COVID-19 with neutralizing monoclonal antibodies

Corti, D., Purcell, L. A., Snell, G., & Veesler, D. (2021) · Cell · doi:10.1016/j.cell.2021.05.005 · Cited by 375 · see citing works

Antibodies to combat viral infections: development strategies and progress

Pantaleo, G., Correia, B. E., Fenwick, C. W., Joo, V., & Perez, L. H. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00495-3 · Cited by 286 · see citing works

Monoclonal antibody therapies against SARS-CoV-2

Focosi, D., McConnell, S. A., Casadevall, A., Cappello, E., Valdiserra, G., & Tuccori, M. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00311-5 · Cited by 262 · see citing works

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

Cameroni, E., Bowen, J. E., Rosen, L. E., Saliba, C., Zepeda, S. K., Culap, K., Pinto, D., VanBlargan, L. A., Marco, A. D., di Iulio, J., et al. (2021) · Nature · doi:10.1038/d41586-021-03825-4 · Cited by 247 · see citing works

Imprinted antibody responses against SARS-CoV-2 Omicron sublineages

Park, Y., Pinto, D., Walls, A. C., Liu, Z., Marco, A. D., Benigni, F., Zatta, F., Silacci-Fregni, C., Bassi, J., Sprouse, K. R., et al. (2022) · Science · doi:10.1126/science.adc9127 · Cited by 225 · see citing works

Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection

Greaney, A. J., Loes, A. N., Gentles, L. E., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abi9915 · Cited by 244 · see citing works

The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies

Copin, R., Baum, A., Wloga, E., Pascal, K. E., Giordano, S., Fulton, B. O., Zhou, A., Negron, N., Lanza, K., Chan, N., et al. (2021) · Cell · doi:10.1016/j.cell.2021.06.002 · Cited by 212 · see citing works

Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection

Hwang, Y., Lu, R., Su, S.-C., Chiang, P.-Y., Ko, S.-H., Ke, F.-Y., Liang, K.-H., Hsieh, T.-Y., & Wu, H. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-021-00784-w · Cited by 236 · see citing works

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

Cao, Y., Wang, J., Jian, F., Xiao, T., Song, W., Yisimayi, A., Huang, W., Li, Q., Wang, P., An, R., et al. (2021) · Nature · doi:10.1038/d41586-021-03796-6 · Cited by 227 · see citing works

Learning from prepandemic data to forecast viral escape

Thadani, N. N., Gurev, S. F., Notin, P., Youssef, N., Rollins, N. J., Ritter, D., Sander, C., Gal, Y., & Marks, D. S. (2023) · Nature · doi:10.1038/s41586-023-06617-0 · Cited by 212 · see citing works

Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant

Saito, A., Tamura, T., Zahradník, J., Deguchi, S., Tabata, K., Anraku, Y., Kimura, I., Ito, J., Yamasoba, D., Nasser, H., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.10.003 · Cited by 186 · see citing works

Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines

Walls, A. C., Miranda, M. C., Schäfer, A., Pham, M. N., Greaney, A., Arunachalam, P. S., Navarro, M.-J., Tortorici, M. A., Rogers, K., O’Connor, M. A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.09.015 · Cited by 185 · see citing works

An antibody-escape estimator for mutations to the SARS-CoV-2 receptor-binding domain

Greaney, A. J., Starr, T. N., & Bloom, J. D. (2022) · Virus Evolution · doi:10.1093/ve/veac021 · Cited by 147 · see citing works

Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529

Zhou, T., Wang, L., Misasi, J., Pegu, A., Zhang, Y., Harris, D. R., Olia, A. S., Talana, C. A., Yang, E. S., Chen, M., et al. (2022) · Science · doi:10.1126/science.abn8897 · Cited by 160 · see citing works

SARS-CoV-2 Mutations and Their Impact on Diagnostics, Therapeutics and Vaccines

Thakur, S., Sasi, S., Pillai, S. G., Nag, A., Shukla, D., Singhal, R., Phalke, S., & Velu, G. S. K. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.815389 · Cited by 158 · see citing works

A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies

Kumari, M., Lu, R., Li, M., Huang, J., Hsu, F., Ko, S.-H., Ke, F.-Y., Su, S.-C., Liang, K.-H., Yuan, J. P., et al. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00852-9 · Cited by 157 · see citing works

Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains

Case, J. B., Mackin, S., Errico, J. M., Chong, Z., Madden, E. A., Whitener, B. M., Guarino, B., Schmid, M., Rosenthal, K., Ren, K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31615-7 · Cited by 144 · see citing works

Antibody-mediated neutralization of SARS-CoV-2

Gruell, H., Vanshylla, K., Weber, T., Barnes, C. O., Kreer, C., & Klein, F. (2022) · Immunity · doi:10.1016/j.immuni.2022.05.005 · Cited by 145 · see citing works

Two Years into the COVID-19 Pandemic: Lessons Learned

da Silva, S. J. R., do Nascimento, J. C. F., Mendes, R. P. G., Guarines, K. M., da Silva, C. T. A., da Silva, P. G., de Magalhães, J. J. F., Vigar, J. R. J., Silva‐Júnior, A., Kohl, A., et al. (2022) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.2c00204 · Cited by 140 · see citing works

Convergent Evolution in SARS-CoV-2 Spike Creates a Variant Soup from Which New COVID-19 Waves Emerge

Focosi, D., Quiroga, R., McConnell, S. A., Johnson, M. C., & Casadevall, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032264 · Cited by 132 · see citing works

Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial

Holland, T. L., Ginde, A. A., Paredes, R., Murray, T. A., Engen, N. W., Grandits, G., Vekstein, A. M., Ivey, N., Mourad, A., Sandkovsky, U., et al. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00215-6 · Cited by 122 · see citing works

Persistent immune imprinting occurs after vaccination with the COVID-19 XBB.1.5 mRNA booster in humans

Tortorici, M. A., Addetia, A., Seo, A. J., Brown, J. T., Sprouse, K., Logue, J., Clark, E., Franko, N., Chu, H. Y., & Veesler, D. (2024) · Immunity · doi:10.1016/j.immuni.2024.02.016 · Cited by 124 · see citing works

A large-scale systematic survey reveals recurring molecular features of public antibody responses to SARS-CoV-2

Wang, Y., Yuan, M., Lv, H., Peng, J., Wilson, I. A., & Wu, N. C. (2022) · Immunity · doi:10.1016/j.immuni.2022.03.019 · Cited by 114 · see citing works

Stopping pandemics before they start: Lessons learned from SARS-CoV-2

Edwards, A. M., Baric, R. S., Saphire, E. O., & Ulmer, J. B. (2022) · Science · doi:10.1126/science.abn1900 · Cited by 107 · see citing works

Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals

Chen, E. C., Gilchuk, P., Zost, S. J., Suryadevara, N., Winkler, E. S., Cabel, C. R., Binshtein, E., Chen, R. E., Sutton, R. E., Rodriguez, J. L., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109604 · Cited by 76 · see citing works

Cumulative SARS-CoV-2 mutations and corresponding changes in immunity in an immunocompromised patient indicate viral evolution within the host

Sonnleitner, S. T., Prelog, M., Sonnleitner, S., Hinterbichler, E., Halbfurter, H., Kopecky, D. B. C., Almanzar, G., Koblmüller, S., Sturmbauer, C., Feist, L., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30163-4 · Cited by 103 · see citing works

Omicron BA.2 (B.1.1.529.2): High Potential for Becoming the Next Dominant Variant

Chen, J., & Wei, G. (2022) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.2c00469 · Cited by 98 · see citing works

A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope

VanBlargan, L. A., Adams, L., Liu, Z.-M., Chen, R. E., Gilchuk, P., Raju, S., Smith, B. K., Zhao, H.-Y., Case, J., Winkler, E. S., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.08.016 · Cited by 95 · see citing works

Methodology-Centered Review of Molecular Modeling, Simulation, and Prediction of SARS-CoV-2

Gao, K., Wang, R., Chen, J., Cheng, L., Frishcosy, J., Huzumi, Y., Qiu, Y., Schluckbier, T., Wei, X., & Wei, G. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00965 · Cited by 91 · see citing works

Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysis

Tao, K., Tzou, P. L., Pond, S. L. K., Ioannidis, J. P. A., & Shafer, R. W. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00926-22 · Cited by 80 · see citing works

Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels

ACTIV-3/TICO Bamlanivimab Study Group*, Lundgren, J. D., Grund, B., Barkauskas, C. E., Holland, T. L., Gottlieb, R., Sandkovsky, U., Brown, S. M., Knowlton, K. U., Self, W. H., et al. (2021) · Annals of Internal Medicine · doi:10.7326/m21-3507 · Cited by 78 · see citing works

SARS-CoV-2 spike conformation determines plasma neutralizing activity elicited by a wide panel of human vaccines

Bowen, J. E., Park, Y., Stewart, C., Brown, J. T., Sharkey, W. K., Walls, A. C., Joshi, A., Sprouse, K. R., McCallum, M., Tortorici, M. A., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.adf1421 · Cited by 81 · see citing works

A broad and potent neutralization epitope in SARS-related coronaviruses

Yuan, M., Zhu, X., He, W., Zhou, P.-P., Kaku, C. I., Capozzola, T., Zhu, C. Y., Yu, X., Liu, H., Yu, W., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2205784119 · Cited by 74 · see citing works

A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants

Schmitz, A. J., Turner, J., Liu, Z.-M., Zhou, J. Q., Aziati, I. D., Chen, R. E., Joshi, A., Bricker, T., Darling, T. L., Adelsberg, D. C., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.08.013 · Cited by 58 · see citing works

Potent human broadly SARS-CoV-2–neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2

Planchais, C., Fernández, I., Bruel, T., de Melo, G. D., Prot, M., Beretta, M., Guardado‐Calvo, P., Dufloo, J., Molinos-Albert, L. M., Backović, M., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20220638 · Cited by 69 · see citing works

A rapid cell-free expression and screening platform for antibody discovery

Hunt, A. C., Vögeli, B., Hassan, A. O., Guerrero, L., Kightlinger, W., Yoesep, D. J., Krüger, A., DeWinter, M. A., Diamond, M., Karim, A. S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38965-w · Cited by 72 · see citing works

A public vaccine-induced human antibody protects against SARS-CoV-2 and emerging variants

Schmitz, A. J., Turner, J. S., Liu, Z., Aziati, I. D., Chen, R. E., Joshi, A., Bricker, T. L., Darling, T. L., Adelsberg, D. C., Alsoussi, W. B., et al. (2021) · doi:10.1101/2021.03.24.436864 · Cited by 72 · see citing works

Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responsesPreprint

Dejnirattisai, W., Huo, J., Zhou, D., Zahradník, J., Supasa, P., Liu, C., Duyvesteyn, H. M. E., Ginn, H. M., Mentzer, A. J., Tuekprakhon, A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.03.471045 · Cited by 69 · see citing works

Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain

Wheatley, A., Pymm, P., Esterbauer, R., Dietrich, M., Lee, W., Drew, D., Kelly, H. G., Chan, L., Mordant, F., Black, K. A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109822 · Cited by 48 · see citing works

Imprinted antibody responses against SARS-CoV-2 Omicron sublineages

Park, Y.-J., Pinto, D., Walls, A. C., Liu, Z., De Marco, A., Benigni, F., Zatta, F., Silacci-Fregni, C., Bassi, J., Sprouse, K. R., et al. (2022) · doi:10.1101/2022.05.08.491108 · Cited by 251 · see citing works

Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations

Dussupt, V., Sankhala, R., Mendez-Rivera, L., Townsley, S. M., Schmidt, F., Wieczorek, L., Lal, K. G., Donofrio, G., Tran, U., Jackson, N. D., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-01068-z · Cited by 66 · see citing works

Pharmacological treatment of COVID-19: an opinion paper

García‐Lledó, A., Gómez‐Pavón, J., del Castillo, J. M. G., Hernández‐Sampelayo, T., Delgado, M. C. M., Martín‐Sánchez, F. J., Martínez‐Sellés, M., Molero, J., Guillén, S. M., Rodríguez‐Artalejo, F., et al. (2021) · Revista Española de Quimioterapia · doi:10.37201/req/158.2021 · Cited by 62 · see citing works

Omicron BA.2 (B.1.1.529.2): high potential to becoming the next dominating variantPreprint

Chen, J., & Wei, G. (2022) · Research Square · doi:10.21203/rs.3.rs-1362445/v1 · Cited by 66 · see citing works

Analysis of SARS-CoV-2 Variants From 24,181 Patients Exemplifies the Role of Globalization and Zoonosis in Pandemics

Colson, P., Fournier, P., Chaudet, H., Delerce, J., Giraud‐Gatineau, A., Houhamdi, L., Andrieu, C., Bréchard, L., Bedotto, M., Prudent, E., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.786233 · Cited by 64 · see citing works

Tixagevimab + Cilgavimab: First Approval

Keam, S. J. (2022) · Drugs · doi:10.1007/s40265-022-01731-1 · Cited by 60 · see citing works

In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B.1.1.529 isolate

Touret, F., Baronti, C., Bouzidi, H. S., & de Lamballerie, X. N. (2022) · Scientific Reports · doi:10.1038/s41598-022-08559-5 · Cited by 57 · see citing works

A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75

Huo, J., Dijokaite-Guraliuc, A., Liu, C., Zhou, D., Ginn, H. M., Das, R., Supasa, P., Selvaraj, M., Nutalai, R., Tuekprakhon, A., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111903 · Cited by 55 · see citing works

A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld™) for COVID-19 Prophylaxis and Treatment

Focosi, D., & Casadevall, A. (2022) · Viruses · doi:10.3390/v14091999 · Cited by 59 · see citing works

In vitro activity of therapeutic antibodies against SARS-CoV-2 Omicron BA.1, BA.2 and BA.5

Touret, F., Baronti, C., Pastorino, B. A. M., Villarroel, P. M. S., Ninove, L., Nougaırède, A., & de Lamballerie, X. N. (2022) · Scientific Reports · doi:10.1038/s41598-022-16964-z · Cited by 55 · see citing works

An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants of concern

Du, W., Hurdiss, D. L., Drabek, D., Mykytyn, A. Z., Kaiser, F. K., González-Hernández, M., Muñoz‐Santos, D., Lamers, M. M., van Haperen, R., Li, W., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abp9312 · Cited by 53 · see citing works

Structural basis for a conserved neutralization epitope on the receptor-binding domain of SARS-CoV-2

Huang, K.-Y. A., Chen, X., Mohapatra, A., Nguyen, H. T. V., Schimanski, L. M., Tan, T. K., Rijal, P., Vester, S. K., Hills, R. A., Howarth, M. R., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-35949-8 · Cited by 48 · see citing works

Computationally restoring the potency of a clinical antibody against Omicron

Desautels, T., Arrildt, K. T., Zemla, A. T., Lau, E. Y., Zhu, F., Ricci, D. P., Cronin, S., Zost, S. J., Binshtein, E., Scheaffer, S. M., et al. (2024) · Nature · doi:10.1038/s41586-024-07385-1 · Cited by 53 · see citing works

Deep mutational scanning for therapeutic antibody engineering

Hanning, K. R., Minot, M., Warrender, A. K., Kelton, W., & Reddy, S. T. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.11.010 · Cited by 51 · see citing works

Human Antibodies for Viral Infections

Crowe, J. E. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042718-041309 · Cited by 52 · see citing works

SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies

Arora, P., Zhang, L., Krüger, N., Rocha, C., Sidarovich, A., Schulz, S. R., Kempf, A. M., Graichen, L., Moldenhauer, A.-S., Cossmann, A., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.04.017 · Cited by 44 · see citing works

Impact of new variants on SARS-CoV-2 infectivity and neutralization: A molecular assessment of the alterations in the spike-host protein interactions

Cheng, M. H., Krieger, J. M., Banerjee, A., Xiang, Y., Kaynak, B., Shi, Y., Arditi, M., & Bahar, I. (2022) · iScience · doi:10.1016/j.isci.2022.103939 · Cited by 38 · see citing works

SARS-CoV-2 E484K Mutation Narrative Review: Epidemiology, Immune Escape, Clinical Implications, and Future Considerations

Yang, W.-T., Huang, W.-H., Liao, T.-L., Hsiao, T.-H., Chuang, H.-N., & Liu, P.-Y. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s344099 · Cited by 45 · see citing works

SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs

Iketani, S., & Ho, D. D. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.03.008 · Cited by 46 · see citing works

COVID‐19 vaccine failure in chronic lymphocytic leukaemia and monoclonal B‐lymphocytosis; humoural and cellular immunity

Shen, Y., Freeman, J. A., Holland, J., Solterbeck, A., Naidu, K., Soosapilla, A., Downe, P., Tang, C., Kerridge, I., Wallman, L., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.18014 · Cited by 47 · see citing works

Host immunological responses facilitate development of SARS-CoV-2 mutations in patients receiving monoclonal antibody treatments

Gupta, A., Konnova, A., Smet, M., Berkell, M., Savoldi, A., Morra, M., averbeke, V. V., Winter, F. D., Peserico, D., Danese, E., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci166032 · Cited by 41 · see citing works

Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineages

Touret, F., Giraud, É., Bourret, J., Donati, F., Tran-Rajau, J., Chiaravalli, J., Lemoine, F., Agou, F., Simon‐Lorière, E., van der Werf, S., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106413 · Cited by 43 · see citing works

Identification of broad, potent antibodies to functionally constrained regions of SARS-CoV-2 spike following a breakthrough infection

Guenthoer, J., Lilly, M., Starr, T. N., Dadonaite, B., Lovendahl, K. N., Croft, J. T., Stoddard, C. I., Chohan, V., Ding, S.-L., Ruiz, F., et al. (2023) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.2220948120 · Cited by 29 · see citing works

COVID-19 therapeutics

Focosi, D., Franchini, M., Maggi, F., & Shoham, S. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00119-23 · Cited by 46 · see citing works

Evolution of Anti-SARS-CoV-2 Therapeutic Antibodies

Almagro, J. C., Mellado‐Sánchez, G., Pedraza‐Escalona, M., & Pérez‐Tapia, S. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179763 · Cited by 43 · see citing works

SARS-CoV-2 variants: biology, pathogenicity, immunity and control

Uraki, R., Korber, B., Diamond, M., & Kawaoka, Y. (2025) · Nature Reviews Microbiology · doi:10.1038/s41579-025-01255-x · Cited by 47 · see citing works

The 15-Months Clinical Experience of SARS-CoV-2: A Literature Review of Therapies and Adjuvants

Inchingolo, A. D., Dipalma, G., Inchingolo, A. M., Malcangi, G., Santacroce, L., D’Oria, M. T., Isacco, C. G., Bordea, I. R., Candrea, S., Scarano, A., et al. (2021) · Antioxidants · doi:10.3390/antiox10060881 · Cited by 40 · see citing works

Patient-derived monoclonal antibody neutralizes SARS-CoV-2 Omicron variants and confers full protection in monkeys

Fenwick, C. W., Turelli, P., Ni, D., Perez, L. H., Lau, K., Hérate, C., Marlin, R., Lana, E., Pellaton, C., Raclot, C., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01198-6 · Cited by 37 · see citing works

Treatments for COVID-19: Lessons from 2020 and new therapeutic options

Salasc, F., Lahlali, T., Laurent, E., Rosa‐Calatrava, M., & Pizzorno, A. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.11.002 · Cited by 36 · see citing works

Treatment and prevention strategies for the COVID 19 pandemic: A review of immunotherapeutic approaches for neutralizing SARS-CoV-2

Baral, P. K., Yin, J., & James, M. N. G. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.07.013 · Cited by 36 · see citing works

Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters

Uraki, R., Kiso, M., Imai, M., Yamayoshi, S., Ito, M., Fujisaki, S., Takashita, E., Ujie, M., Furusawa, Y., Yasuhara, A., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01170-4 · Cited by 37 · see citing works

Structure-based neutralizing mechanisms for SARS-CoV-2 antibodies

Huang, Q., Han, X., & Yan, J. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2125348 · Cited by 36 · see citing works

Antibodies induced by an ancestral SARS-CoV-2 strain that cross-neutralize variants from Alpha to Omicron BA.1

Windsor, I. W., Tong, P., Lavidor, O., Moghaddam, A. S., McKay, L. G. A., Gautam, A. K., Chen, Y., MacDonald, E. A., Yoo, D. K., Griffths, A., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abo3425 · Cited by 36 · see citing works

Monoclonal Antibodies against SARS-CoV-2: Current Scenario and Future Perspectives

Quirós-Roldán, E., Amadasi, S., Zanella, I., Antoni, M. D., Storti, S., Tiecco, G., & Castelli, F. (2021) · Pharmaceuticals · doi:10.3390/ph14121272 · Cited by 35 · see citing works

An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer

Suryadevara, N., Shiakolas, A. R., VanBlargan, L. A., Binshtein, E., Chen, R. E., Case, J., Kramer, K. J., Armstrong, E. C., Myers, L., Trivette, A., et al. (2022) · bioRxiv · doi:10.1172/jci159062 · Cited by 30 · see citing works

A broadly neutralizing antibody protects Syrian hamsters against SARS-CoV-2 Omicron challenge

Zhou, B., Zhou, R., Tang, B., Chan, J. F., Luo, M., Peng, Q., Yuan, S., Liu, H., Mok, B. W.-Y., Chen, B., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31259-7 · Cited by 32 · see citing works

AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019

Levin, M. J., Ustianowski, A., Thomas, S., Templeton, A., Yuan, Y., Seegobin, S., Houlihan, C. F., Menendez-Perez, I., Pollett, S. D., Arends, R. H., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac899 · Cited by 33 · see citing works

Three SARS-CoV-2 antibodies provide broad and synergistic neutralization against variants of concern, including Omicron

Wang, S., Sun, H., Zhang, Y., Yuan, L., Wang, Y., Zhang, T., Wang, S., Zhang, J., Yu, H. J., Xiong, H., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110862 · Cited by 30 · see citing works

Monoclonal antibody therapies for COVID-19: lessons learned and implications for the development of future products

Kelley, B. D., Moor, P. D., Douglas, K., Renshaw, T., & Traviglia, S. L. (2022) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2022.102798 · Cited by 32 · see citing works

Genome-wide CRISPR screen identifies genes synthetically lethal with GRA17, a nutrient channel encoding gene in Toxoplasma

Paredes-Santos, T. C., Bitew, M. A., Swale, C., Rodriguez, F., Krishnamurthy, S., Wang, Y., Maru, P., Sangaré, L. O., & Saeij, J. P. J. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011543 · Cited by 30 · see citing works

Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants

Seki, Y., Yoshihara, Y., Nojima, K., Momose, H., Fukushi, S., Moriyama, S., Wagatsuma, A., Numata, N., Sasaki, K., Kuzuoka, T., et al. (2022) · Med · doi:10.1016/j.medj.2022.04.013 · Cited by 30 · see citing works

Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults

Forte-Soto, P., Albayaty, M., Brooks, D. A., Arends, R. H., Tillinghast, J. S., Aksyuk, A. A., Bouquet, J., Chen, C., Gebre, A., Kubiak, R. J., et al. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad014 · Cited by 32 · see citing works

AZD3152 neutralizes SARS-CoV-2 historical and contemporary variants and is protective in hamsters and well tolerated in adults

Caì, Y., Diallo, S., Rosenthal, K., Ren, K., Flores, D. J., Dippel, A. B., Oganesyan, V., van Dyk, N., Chen, X., Cantu, E. N., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.ado2817 · Cited by 31 · see citing works

DNA-delivered antibody cocktail exhibits improved pharmacokinetics and confers prophylactic protection against SARS-CoV-2

Parzych, E. M., Du, J., Ali, A., Schultheis, K., Frase, D. M., Smith, T. R. F., Cui, J., Chokkalingam, N., Tursi, N. J., Andrade, V. M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33309-6 · Cited by 30 · see citing works

Molecular analysis of a public cross-neutralizing antibody response to SARS-CoV-2

Yuan, M., Wang, Y., Lv, H., Tan, T. J. C., Wilson, I. A., & Wu, N. C. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111650 · Cited by 27 · see citing works

An update on the anti-spike monoclonal antibody pipeline for SARS-CoV-2

Focosi, D., Franchini, M., Casadevall, A., & Maggi, F. (2024) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2024.04.012 · Cited by 31 · see citing works

A guide to COVID ‐19 antiviral therapeutics: a summary and perspective of the antiviral weapons against SARS‐CoV ‐2 infection

Brady, D. K., Gurijala, A. R., Huang, L., Hussain, A. A., Lingan, A. L., Pembridge, O. G., Ratangee, B. A., Sealy, T. T., Vallone, K. T., & Clements, T. P. (2022) · FEBS Journal · doi:10.1111/febs.16662 · Cited by 30 · see citing works

Further antibody escape by Omicron BA.4 and BA.5 from vaccine and BA.1 serumPreprint

Tuekprakhon, A., Huo, J., Nutalai, R., Dijokaite-Guraliuc, A., Zhou, D., Ginn, H. M., Selvaraj, M., Liu, C., Mentzer, A. J., Supasa, P., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.21.492554 · Cited by 31 · see citing works

Structural Immunology of SARS ‐ CoV ‐2

Yuan, M., & Wilson, I. A. (2024) · Immunological Reviews · doi:10.1111/imr.13431 · Cited by 28 · see citing works

Designed mosaic nanoparticles enhance cross-reactive immune responses in mice

Wang, E. J. D., Cohen, A. A., Caldera, L. F., Keeffe, J. R., Rorick, A. V., Adia, Y. M., Gnanapragasam, P. N. P., Björkman, P. J., & Chakraborty, A. K. (2025) · Cell · doi:10.1016/j.cell.2024.12.015 · Cited by 27 · see citing works

Computationally designed proteins mimic antibody immune evasion in viral evolution

Youssef, N., Gurev, S. F., Ghantous, F., Brock, K. P., Jaimes, J. A., Thadani, N. N., Dauphin, A., Sherman, A. C., Yurkovetskiy, L., Soto, D., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.04.015 · Cited by 25 · see citing works

Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition

Kramer, K. J., Johnson, N., Shiakolas, A. R., Suryadevara, N., Periasamy, S., Raju, N., Williams, J. K., Wrapp, D., Zost, S. J., Walker, L. M., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109784 · Cited by 26 · see citing works

Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail

Dong, J., Zost, S. J., Greaney, A. J., Starr, T. N., Dingens, A. S., Chen, E. C., Chen, R. E., Case, J. B., Sutton, R. E., Gilchuk, P., et al. (2021) · doi:10.1101/2021.01.27.428529 · Cited by 55 · see citing works

SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms

Clark, S., Clark, L., Pan, J., Coscia, A., McKay, L. G. A., Shankar, S., Johnson, R. I., Brusic, V., Choudhary, M., Regan, J., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.027 · Cited by 176 · see citing works

Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain

Wheatley, A., Pymm, P., Esterbauer, R., Dietrich, M., Lee, W., Drew, D., Kelly, H. G., Chan, L., Mordant, F., Black, K. A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109822 · Cited by 48 · see citing works

Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies

Cerutti, G., Rapp, M., Guo, Y., Bahna, F. A., Bimela, J. S., Reddem, E. R., Yu, J., Wang, P., Liu, L., Huang, Y., et al. (2021) · Structure · doi:10.1016/j.str.2021.05.014 · Cited by 58 · see citing works

Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition

Kramer, K. J., Johnson, N., Shiakolas, A. R., Suryadevara, N., Periasamy, S., Raju, N., Williams, J. K., Wrapp, D., Zost, S. J., Walker, L. M., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109784 · Cited by 26 · see citing works